Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

4Q preview: Amgen, Biogen, BMS, Celgene, Novartis, Pfizer and Roche

This article was originally published in Scrip

Executive Summary

The full-year reporting season began on 21 January with Johnson & Johnson reporting a strong showing from pharma sales (helped from an expected short-lived boost from its hepatitis C newcomer Olysio (simeprevir). Its fourth-quarter figures already showed the effects of "currency headwinds" that are expected to impact many in its pharma peer set in 2015. It warned that foreign exchange shifts with the recent strong appreciation of the US dollar will weigh on its 2015 figures. Goldman Sachs analysts believe big US pharma companies will take a 4-6% hit from currency headwinds in 2015, with about 37-50% of the top line hit flowing to EPS.

You may also be interested in...



2020 Vision For Biopharma

Crystal ball gazing is a tricky, sometimes futile, endeavor. No one knows what the future holds, but there are consistent scenarios emerging that are being debated by industry leaders as they try to foretell and outsmart key market catalysts expected to ripple across the biopharma sector in 2020. With insights from executives, investors and consultancies, as well as our own experts, In Vivo can paint a picture of biopharma wins and woes expected in the new year and new decade.

Accessing CAR-T Therapies

Infographic: There are two CAR-T therapies on the market, both of which secured their first approvals in 2017. The pipeline of autologous and allogeneic CAR-T options is busy with several candidates in clinical studies. However, getting approval is only one part of getting these breakthrough therapies to patients.

Taking Aim At Advanced Therapies

Dmitry Kuzmin, managing partner, and Owen Smith, investment director, talk to In Vivo about 4BIO’s approach to venture investing in the biopharma sector: successes, red flags and targets for its second fund.

Topics

Related Companies

UsernamePublicRestriction

Register

SC027597

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel